The AARP, the US association for retired citizens, will ask Congress to makes changes to the new Medicare prescription drug benefit plan, according to its policy director, John Rother, who told the Washington Post that the group wants assets such as a house excluded when the determination is made as to whether a senior qualifies for special low-income subsidies. Additionally, the AARP wants to reopen the discussion on whether Medicare should negotiate directly with drugmakers over prices, rather than have companies negotiate prices with the insurance plans that sell the drug benefit to patients.
AARP, which had some influence on the creation of the current program, did endorse the legislation that passed through Congress, but also noted that it might want to "build on it in the future."
The comments to the Post came as AARP chief executive Bill Novelli said, in a discussion of the group's 2006 legislative agenda, that the 2003 Medicare law should be revised to allow the Department of Health and Human Services to negotiate prices with drug companies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze